[Ip-health] webinar: R&D costs of cancer medicines: how does it compare with sales income?

marcela vieira marcelacfvieira at gmail.com
Thu Mar 7 10:51:01 PST 2019

Dear ip-health readers,

We are pleased to invite you to the next webinar organized by the Knowledge
Network on Innovation and Access to Medicines, presenting recent research
and analysis on topics relating to pharmaceuticals policy.

R&D costs of cancer medicines: how does it compare with sales income?

Thursday 21 March| 4:00pm-5:15pm CET | 11:00am-12:15pm EDT

To join the webinar, please register here


Kiu Tay-Teo, MPubHlth, PhD

Technical Officer at Innovation, Access, and Use Unit of the Department of
Essential Medicines & Health Products, World Health Organization


Comparison of Sales Income and Research and Development Costs for
FDA-Approved Cancer Drugs Sold by Originator Drug Companies (January 2019)



The costs of R&D have been a recurrent point of discussion in the
continuing debate about the high prices of medicines. High costs and risks
of R&D have been used to justify the high prices of cancer drugs. Attempts
to quantify R&D costs for medicines have produced highly variable
estimates. There is also a lack of information regarding the overall
lifetime return on R&D investment, and its potential implications on access
and innovation.

Dr. Kiu Tay-Teo will present a recently published paper (above) that
compared the cumulative sales incomes of cancer medicines approved by the
US FDA between 1989 and 2017 with the estimated R&D costs reported in the
literature. He will describe the methodology used in the study and
highlight the main findings, which include an estimation of the return on
R&D investment and what it means from the perspective of patient access to
medicines and future innovation. The study concluded that the observed
returns for originator companies are far in excess of possible R&D costs.
It argued that lowering prices of cancer medicines and facilitating greater
competition are essential for improving patient access, health system’s
financial sustainability, and future innovation.

Who should consider attending?

Those interested in learning more about:

- Medicines prices

- Return on pharmaceutical R&D investments

- Cancer medicines

The webinar is free and will be held in English. Participants will be able
to pose questions orally and in writing, and the speaker will respond to a
selection of these during the second half of the event. Recordings of all
webinars will be made available at the Global Health Centre webpage
After registering, you will receive a confirmation email with additional
information on how to join the webinar using the Zoom platform.

We hope you will be able to join us for this informative presentation. This
event is part of the webinar series of the Knowledge Network for Innovation
and Access to Medicines, a project of the Global Health Centre at the
Graduate Institute of Geneva. Suggestions for speakers and topics for
future webinars are welcome at globalhealthresearch at graduateinstitute.ch.
Marcela Vieira
Project Coordinator
Knowledge Network for Innovation and Access to Medicines
Global Health Centre, Research
Graduate Institute of International and Development Studies
marcela.vieira at graduateinstitute.ch


More information about the Ip-health mailing list